A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumoursEdwina N. Scott, Johann S. de Bono, Candice McCoy et al.|Cancer Chemotherapy and Pharmacology|2009Cited by 34